🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan flag Japan · Delayed Price · Currency is JPY
2,056.00
-7.00 (-0.34%)
Nov 18, 2026, 3:30 PM JST

Santen Pharmaceutical Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
39,18537,56135,85326,703-14,98327,189
Depreciation & Amortization
18,11918,35817,94818,17817,24917,055
Loss (Gain) From Sale of Assets
3,8413,8411,3027,77934,560232
Loss (Gain) on Equity Investments
--6857,5752,3621,604
Other Operating Activities
-9,464-7,642-12,288-12,287-7,990-10,318
Change in Accounts Receivable
7922,66918,51218,384-6,443-1,965
Change in Inventory
-5,465-10,025-8,381-1,369-1,1445,383
Change in Accounts Payable
673-4,024-9,586-2,3691,6902,748
Change in Other Net Operating Assets
1,9562,76216,88310,05511,8464,115
Operating Cash Flow
49,63743,50060,92872,64937,14746,043
Operating Cash Flow Growth
7.46%-28.60%-16.13%95.57%-19.32%18.64%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-8,332-6,844-6,662-9,319-17,277-17,344
Cash Acquisitions
----207-3,470-2,969
Sale (Purchase) of Intangibles
-4,353-6,469-4,357-572-7,311-18,497
Investment in Securities
5783603,1523,8261,5602,803
Other Investing Activities
50-21-356127-279838
Investing Cash Flow
-12,057-12,974-8,223-6,145-26,777-35,169

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-----10,460
Long-Term Debt Issued
----15,63910,000
Total Debt Issued
----15,63920,460
Short-Term Debt Repaid
-----11,278-
Long-Term Debt Repaid
---158-2,112--
Total Debt Repaid
---158-2,112-11,278-
Net Debt Issued (Repaid)
---158-2,1124,36120,460
Repurchase of Common Stock
-5,959-32,797-37,883-16,962-26,007-
Common Dividends Paid
-12,273-12,642-12,111-11,881-12,607-11,994
Other Financing Activities
-3,932-3,909-3,155-3,076-2,967-2,909
Financing Cash Flow
-22,164-49,348-53,307-34,031-37,2205,557

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
3,3716,700-9834,2061,7393,694
Miscellaneous Cash Flow Adjustments
-690----1
Net Cash Flow
18,097-12,122-1,58536,679-25,11120,126

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
41,30536,65654,26663,33019,87028,699
Free Cash Flow Growth
6.40%-32.45%-14.31%218.72%-30.76%-17.22%
Free Cash Flow Margin
13.91%12.57%18.09%20.97%7.12%10.78%
Free Cash Flow Per Share
128.18111.63155.18172.0351.2971.67
Levered Free Cash Flow
26,41317,27340,19157,84910,0076,630
Unlevered Free Cash Flow
27,23018,14240,86758,36910,3056,786

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
1,4891,2631,093830465240
Cash Income Tax Paid
8,9737,43712,18812,1087,81810,246
Change in Working Capital
-2,044-8,61817,42824,7015,94910,281